VIRACEPT Drug Patent Profile

Which patents cover Viracept, and what generic alternatives are available?

Viracept is a drug marketed by Agouron Pharms and is included in three NDAs.

The generic ingredient in VIRACEPT is nelfinavir mesylate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nelfinavir mesylate profile page.

Summary for VIRACEPT

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	43
Patent Applications:	4,991
Drug Prices:	Drug price information for VIRACEPT
What excipients (inactive ingredients) are in VIRACEPT?	VIRACEPT excipients list
DailyMed Link:	VIRACEPT at DailyMed

See drug prices for VIRACEPT

Recent Clinical Trials for VIRACEPT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mayo Clinic	Phase 1
The University of Texas Health Science Center, Houston	Phase 2
Joseph Anthony Lucci III	Phase 2

See all VIRACEPT clinical trials

Pharmacology for VIRACEPT

Drug Class	Protease Inhibitor
Mechanism of Action	Cytochrome P450 3A Inhibitors HIV Protease Inhibitors

US Patents and Regulatory Information for VIRACEPT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Agouron Pharms	VIRACEPT	nelfinavir mesylate	POWDER;ORAL	020778-001	Mar 14, 1997		DISCN	No	No
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779-001	Mar 14, 1997		RX	Yes	Yes
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	021503-001	Apr 30, 2003		RX	Yes	Yes

Expired US Patents for VIRACEPT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779-001	Mar 14, 1997	5,952,343*PED
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	021503-001	Apr 30, 2003	6,162,812*PED
Agouron Pharms	VIRACEPT	nelfinavir mesylate	POWDER;ORAL	020778-001	Mar 14, 1997	5,484,926*PED
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	021503-001	Apr 30, 2003	5,484,926*PED
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779-001	Mar 14, 1997	6,162,812*PED
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779-001	Mar 14, 1997	5,484,926*PED

International Patents for VIRACEPT

See the table below for patents covering VIRACEPT around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	9407815
Romania	119363	DERIVAT DE DECAHIDROIZOCHINOLINĂ, COMPOZIŢIE FARMACEUTICĂ ŞI UTILIZARE (DECAHYDROISOQUINOLINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF)
Japan	H09501443
Taiwan	432049
Japan	3703647
Canada	2173328	INHIBITEURS DE LA PROTEASE DU VIH (HIV PROTEASE INHIBITORS)

VIRACEPT Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of HIV Drugs: A Focus on VIRACEPT

Introduction to HIV Drugs Market

The global HIV drugs market is a significant sector within the pharmaceutical industry, driven by the increasing prevalence of HIV and the continuous need for effective treatments. Here, we will delve into the market dynamics and financial trajectory, with a specific focus on VIRACEPT, a notable HIV drug.

Global HIV Drugs Market Overview

The global HIV drugs market was valued at $32.8 billion in 2022 and is projected to reach $51.1 billion by 2032, growing at a CAGR of 4.5% from 2023 to 2032[1].

Market Drivers

Several factors drive the growth of the HIV drugs market:

• Increasing Prevalence of HIV: According to UNAIDS, 39 million people globally were living with HIV in 2022, and 1.3 million people became newly infected with HIV in the same year[1].
• Government Initiatives: Increased awareness and diagnosis initiatives by government associations contribute to the demand for HIV drugs.
• Advancements in Treatment: Continuous research and development in HIV treatments, including multi-class combination drugs, have improved patient outcomes and driven market growth[1].

Regional Market Analysis

North America

North America held the largest market share in 2022, driven by the presence of major pharmaceutical companies like AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Johnson & Johnson, and Merck & Co., Inc. The region benefits from advanced healthcare facilities, high healthcare expenditure, and a sophisticated reimbursement structure[1].

Asia-Pacific

The Asia-Pacific region is expected to witness the highest CAGR during the forecast period due to the large population base, particularly in China and India, and increasing public-private investments in the healthcare sector[1].

Distribution Channels

Hospital Pharmacies

Hospital pharmacies dominated the HIV drugs market in 2022 due to high sales of drugs from these channels and the high number of HIV patients seeking treatment in hospitals[1].

Online Pharmacies

Online pharmacies are expected to witness significant growth due to convenience, improvements in logistics, ease of payment options, and heavy discounts offered by these platforms[1].

VIRACEPT: A Specific HIV Drug

VIRACEPT (Nelfinavir Mesylate) is a protease inhibitor used in the treatment of HIV-1 infection. Here’s a closer look at its market dynamics and financial trajectory:

Historical Context of VIRACEPT

VIRACEPT was approved by the FDA in 1997 and was one of the key drugs in the early treatment regimens for HIV. It was developed by Agouron Pharmaceuticals, which was later acquired by Pfizer Inc.[5].

Market Performance

During its peak, VIRACEPT was a significant player in the HIV protease inhibitor market. However, its market share declined with the introduction of newer, more effective, and easier-to-administer drugs.

Financial Trajectory

The financial performance of VIRACEPT has been impacted by several factors:

• Patent Expiry: The patent for VIRACEPT expired, leading to the introduction of generic alternatives, which reduced its market share and revenue.
• Newer Therapies: The development of newer HIV treatments with better efficacy and fewer side effects has shifted market preference away from older drugs like VIRACEPT.
• Market Competition: The HIV drugs market is highly competitive, with multiple classes of drugs available, including non-nucleoside reverse transcriptase inhibitors (NNRTIs) and HIV integrase strand transfer inhibitors (INSTIs), which have become more popular due to their effectiveness and ease of use[4].

Impact of Genericization

The genericization of VIRACEPT has significantly reduced its revenue. Generic drugs offer a cheaper alternative, leading to a decline in the sales of branded drugs. This trend is consistent with the broader pharmaceutical market, where generic drugs have increased their share of spending over the years[3].

Current Market Status

While VIRACEPT is no longer a dominant player in the HIV drugs market, it still holds a place in certain treatment regimens, particularly in regions where access to newer drugs is limited. However, its financial trajectory is largely influenced by the availability of generic versions and the preference for newer, more advanced treatments.

Key Takeaways

• The global HIV drugs market is driven by increasing prevalence, government initiatives, and advancements in treatment.
• North America dominates the market, but Asia-Pacific is expected to grow at the highest rate.
• VIRACEPT, once a key player, has seen its market share decline due to patent expiry, genericization, and the introduction of newer therapies.
• The financial trajectory of VIRACEPT is characterized by reduced revenue and market share in the face of increasing competition.

FAQs

1. What is the current size and projected growth of the global HIV drugs market? The global HIV drugs market was valued at $32.8 billion in 2022 and is expected to reach $51.1 billion by 2032, growing at a CAGR of 4.5% from 2023 to 2032[1].

2. Which region dominates the HIV drugs market? North America currently dominates the HIV drugs market, but Asia-Pacific is expected to witness the highest CAGR during the forecast period[1].

3. What factors have impacted the market share of VIRACEPT? The market share of VIRACEPT has been impacted by patent expiry, the introduction of generic alternatives, and the development of newer, more effective HIV treatments[3].

4. How has the genericization of drugs affected the HIV market? Genericization has led to increased competition and reduced revenue for branded drugs like VIRACEPT, as generic alternatives offer a cheaper and often equally effective option[3].

5. What are the key distribution channels for HIV drugs? Hospital pharmacies currently dominate the market, but online pharmacies are expected to grow significantly due to convenience and other factors[1].

Cited Sources:

1. Allied Market Research. HIV Drugs Market Size, Share and Growth Analysis | Report, 2032.
2. Washington State Health Care Authority. Review of Prescription Drug Costs and Summary of Potential Strategies.
3. IQVIA. Drug Expenditure Dynamics 1995-2020: Understanding Medicine Spending in Context.
4. GlobeNewswire. Outlook on the HIV Drugs Global Market to 2027 - Opportunity Analysis and Industry Forecast.